Logo

GSK and Vir Report Initiation of EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19

Share this

GSK and Vir Report Initiation of EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19

Shots:

  • The rolling review will assess sotrovimab in adults and adolescents (aged 12yrs.) with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. The rolling review will support a formal MAA
  • EMA’s CHMP will review the data and the decision to start the rolling review is based on a P-III COMET-ICE study that demonstrated an 85% reduction in hospitalizations over 24hrs. or deaths in those receiving sotrovimab vs PBO
  • Additionally- the CHMP is also reviewing sotrovimab under Article 5(3) of Regulation 726/2004 The companies will continue discussions with global regulators to make sotrovimab available to patients with COVID-19

  Ref: GSK | Image: GSK

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions